You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSecretin
Accession NumberDB00021  (BIOD00039, BTD00039)
TypeBiotech
GroupsApproved, Investigational
Description

This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine’s contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered.

Protein structureDb00021
Protein chemical formulaC130H219N43O42
Protein average weight3056.4000
Sequences
>DB00021 sequence
HSDGTFTSELSRLRDSARLQRLLQGLV
Download FASTA Format
SynonymsNot Available
SaltsNot Available
Brand names
NameCompany
SecreFloRepligen Corp
SecremaxRepligen Corp
Brand mixturesNot Available
Categories
CAS numberNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassOrganic Acids
ClassCarboxylic Acids and Derivatives
SubclassAmino Acids, Peptides, and Analogues
Direct parentPeptides
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionNot Available
Pharmacology
IndicationFor diagnosis of pancreatic exocrine dysfunction and gastrinoma
PharmacodynamicsUsed in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach.
Mechanism of actionSecretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
Manufacturers
  • Ferring pharmaceuticals inc
  • Chirhoclin inc
Packagers
  • Professional Co.
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous
Prices
Unit descriptionCostUnit
Secretin-mannitol powder1.43USDg
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
hydrophobicity-0.463Not Available
isoelectric point9.45Not Available
References
Synthesis Reference

Martin Bickel, Rolf Geiger, Richard Leeb, Walter Petri, “Secretin preparations with intensified and protracted action, process for their manufacture, their use as well as dihydroxybenzoyl-L-tyrosine.” U.S. Patent US4302448, issued August, 1964.

US4302448
General ReferenceNot Available
External Links
ResourceLink
PharmGKBPA164760844
Drug Product Database874000
RxListhttp://www.rxlist.com/cgi/generic3/secretin.htm
Drugs.comhttp://www.drugs.com/human_secretin.html
WikipediaSecretin
ATC CodesV04CK01
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
ClidiniumAnticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely.
TiotropiumThe stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
TolterodineThe stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
TrihexyphenidylThe stimulatory effect of Secretin may be reduced by anticholinergics such as Trihexyphenidyl. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
TrimethobenzamideThe stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
TrospiumThe stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Food InteractionsNot Available

Targets

1. Secretin receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Secretin receptor P47872 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 13, 2013 10:48